BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33212301)

  • 21. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
    Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
    Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
    Chhabra A; Yang L; Wang P; Comin-Anduix B; Das R; Chakraborty NG; Ray S; Mehrotra S; Yang H; Hardee CL; Hollis R; Dorsky DI; Koya R; Kohn DB; Ribas A; Economou JS; Baltimore D; Mukherji B
    J Immunol; 2008 Jul; 181(2):1063-70. PubMed ID: 18606658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.
    Chhabra A; Mukherji B; Batra D
    Expert Opin Ther Targets; 2017 Feb; 21(2):117-129. PubMed ID: 27935327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection of aberrant class II restricted CD8+ T cells in NOD mice expressing a glutamic acid decarboxylase (GAD)65-specific T cell receptor transgene.
    Ranheim EA; Tarbell KV; Krogsgaard M; Mallet-Designe V; Teyton L; McDevitt HO; Weissman IL
    Autoimmunity; 2004 Dec; 37(8):555-67. PubMed ID: 15763918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
    Bot A; Casares S; Bot S; von Boehmer H; Bona C
    J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
    van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
    Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
    Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
    Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.